Antibacterial Resistance Leadership Group

Experts dedicated to prioritizing, designing, and executing clinical research that will reduce the public health threat of antibacterial resistance.

[Antibacterial Resistance Leadership Group @ARLGnetwork]

📢 New #ARLGNetwork MASTERMIND-RING results at #IDWeek2026: On Saturday, Oct. 24 at 2:30 pm ET, Michael Satlin, MD, will present findings on assays to predict ciprofloxacin resistance in Neisseria gonorrhoeae. View a list of ARLG member presentations🔗https://t.co/3brNkhuSmz

[Antibacterial Resistance Leadership Group @ARLGnetwork]

📢 New #ARLGNetwork MASTERMIND-Pneumonia study results at #IDWeek2026: On Thurs., Oct. 22, 12:15 pm ET, Kimberly Hanson, MD, MHS, will present findings on novel tests for diagnosing ventilator-associated pneumonia. View a list of ARLG member presentations🔗https://t.co/3brNkhuSmz

[Antibacterial Resistance Leadership Group @ARLGnetwork]

Next week at #IDWeek2026: #ARLGnetwork Trialist in Training Pranita Tamma, MD, MHS, will deliver the Caroline B. Hall Lecture, “Antimicrobial Resistance: The Next Pandemic Is Already Here,” on Oct. 22 at 3:15 pm ET. See a list of ARLG member presentations🔗https://t.co/3brNkhuSmz

[Antibacterial Resistance Leadership Group @ARLGnetwork]

An #ARLGnetwork scoping review in @npjAMR maps low-cost approaches for detecting #AMR in bacterial infections in resource-limited settings & proposes the REACH checklist to strengthen reporting across AMR diagnostic development🔗https://t.co/ML5IGtQQd1

[Antibacterial Resistance Leadership Group @ARLGnetwork]

✅Enrollment is complete for MASTERMIND-RING, an #ARLGnetwork study evaluating investigational reflex tests to detect genetic markers that predict ciprofloxacin resistance or susceptibility in Neisseria gonorrhoeae. Learn more about ARLG studies🔗https://t.co/JqPydsYFtD

[Antibacterial Resistance Leadership Group @ARLGnetwork]

A global #ARLGnetwork POP study in @JIDJournal found reduced susceptibility to cefiderocol is present worldwide, raising concerns about its use as a last resort antibiotic for patients with carbapenem-resistant P. aeruginosa infections🔗https://t.co/ML5IGtQQd1

[Antibacterial Resistance Leadership Group @ARLGnetwork]

📰ICYMI: The latest #ARLGnetwork newsletter is on our website. Read about ARLG Co-PI Dr. Vance Fowler’s @ISAC_world award, recent research in @JAMAnetwork and @OFIDJournal, clinical trial site and member spotlights, and more network news: https://t.co/Hj4H0FE5Yd
#AMR #IDTwitter

[Antibacterial Resistance Leadership Group @ARLGnetwork]

In this #ARLGnetwork spotlight, Thomas Holland, MD, MSc-GH, @DukeMedSchool reflects on 14 years with ARLG & shares what drives his work in #AMR. As a PI, mentor, & Gram-Positive Committee Chair, he’s making important contributions to the ARLG 🔗 https://t.co/uW20EaerUu

[Antibacterial Resistance Leadership Group @ARLGnetwork]

The #ARLGnetwork FAST trial evaluated rapid vs. standard antimicrobial susceptibility testing for gram-negative bloodstream infections. Read the results and check out the highlights in a @JAMAnetwork editorial, podcast, and research summary🔗https://t.co/yJtmkMRrZL

[Antibacterial Resistance Leadership Group @ARLGnetwork]

✅Study Milestone: Enrollment has closed for #ARLGnetwork OPTIMIZE-GNI, a Phase IV study of cystatin C–guided beta-lactam dosing in critically ill adults with suspected or documented #AMR Gram-negative infections. Learn more about ARLG research🔗https://t.co/JqPydsZdjb

[Antibacterial Resistance Leadership Group @ARLGnetwork]

▶️The #ARLGnetwork Innovations in Diagnostic Trials recording is now available! Presented by Drs. Michael Satlin @WeillCornell, Sarah Doernberg @UCSFHospitals & Ritu Banerjee @VUMCDiscoveries & moderated by Dr. Robin Patel @MayoClinic🔗https://t.co/grbhZbSaug

[Antibacterial Resistance Leadership Group @ARLGnetwork]

In this #ARLGnetwork member spotlight, Sarah Doernberg, MD, MAS, @UCSF, a longtime ARLG investigator & mentor, shares how her work in diagnostics, treatment, antimicrobial stewardship, & patient-reported outcomes supports the fight against #AMR🔗https://t.co/YNEO2U8dEa

[Antibacterial Resistance Leadership Group @ARLGnetwork]

How can RCTs better reflect what matters most to patients? An editorial in @OFIDJournal highlights the #ARLGnetwork’s application of the Desirability of Outcome Ranking (DOOR) framework to trials in acute bacterial skin and skin structure infections🔗 https://t.co/U7ik17kwU1

[Antibacterial Resistance Leadership Group @ARLGnetwork]

An #ARLGnetwork study in @OFIDJournal applies the DOOR method to trials in acute bacterial skin and skin structure infections (ABSSSI), offering a patient-centered benefit-risk framework that may add perspective beyond traditional clinical outcomes🔗https://t.co/ML5IGtRo2z

[Antibacterial Resistance Leadership Group @ARLGnetwork]

How do patients and clinicians describe the impact of complicated UTIs on quality of life? An #ARLGnetwork study in @JAMANetworkOpen highlights gaps that could inform patient-centered trial outcomes & improve patient-clinician communication🔗https://t.co/ML5IGtQQd1

[Antibacterial Resistance Leadership Group @ARLGnetwork]

🔦New #ARLGnetwork clinical trial site spotlight: Dr. Natalie E. West & her research team @HopkinsMedicine supported PHAGE, a clinical trial exploring bacteriophage therapy for people with #CysticFibrosis & chronic Pseudomonas aeruginosa infection🔗https://t.co/702Hn4Bq2L

[Antibacterial Resistance Leadership Group @ARLGnetwork]

Congratulations to #ARLGnetwork Co-PI Vance Fowler, MD, MHS, recipient of the @ISAC_world 2026 Hamao Umezawa Memorial Award, ISAC’s highest honor for contributions to antimicrobial chemotherapy. Dr. Fowler will deliver the award plenary at ICC 2026🔗https://t.co/SseJK4CaEl

[Antibacterial Resistance Leadership Group @ARLGnetwork]

📣 Due Aug. 28 – Attendance grant apps for @ESCMID postgrad course on clinical trials. The course will be led by #ARLGnetwork members Drs. Angela Huttner, Thomas Holland, and @davidantibiotic with other experts in #InfectiousDiseases and #Microbiology🔗https://t.co/PqCPAf43Kd

[Antibacterial Resistance Leadership Group @ARLGnetwork]

The #ARLGnetwork PROOF study investigated the pharmacokinetics, safety & side effects of 2 dosing regimens of fosfomycin, a treatment for UTIs. This research can help doctors choose dosing regimens that are safe & appropriate for their patients. Learn more https://t.co/3CBtnWidY9

[Antibacterial Resistance Leadership Group @ARLGnetwork]

The #ARLGnetwork PROVIDE study found the ideal vancomycin range to target on day 2 of treatment to maximize effectiveness while reducing the risk of kidney injury, improving the care of adults hospitalized with MRSA blood infections. Learn more: https://t.co/d0leMzF2d9